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Abstract
Epilepsy is a devastating disease, currently treated with medications, surgery or electrical stimulation. None of these
approaches is totally effective and our ability to control seizures remains limited and complicated by frequent side effects.
The emerging revolutionary technique of optogenetics enables manipulation of the activity of specific neuronal populations
in vivo with exquisite spatiotemporal resolution using light. We used optogenetic approaches to test the role of
hippocampal excitatory neurons in the lithium-pilocarpine model of acute elicited seizures in awake behaving rats.
Hippocampal pyramidal neurons were transduced in vivo with a virus carrying an enhanced halorhodopsin (eNpHR),
a yellow light activated chloride pump, and acute seizure progression was then monitored behaviorally and
electrophysiologically in the presence and absence of illumination delivered via an optical fiber. Inhibition of those
neurons with illumination prior to seizure onset significantly delayed electrographic and behavioral initiation of status
epilepticus, and altered the dynamics of ictal activity development. These results reveal an essential role of hippocampal
excitatory neurons in this model of ictogenesis and illustrate the power of optogenetic approaches for elucidation of seizure
mechanisms. This early success in controlling seizures also suggests future therapeutic avenues.
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Introduction
Epilepsy is one of the most common neurological disorders and
has severe and devastating manifestations. It is characterized by
recurrent seizures and is presently treated by medications, surgery
or electrical stimulation. Unfortunately, our ability to control
seizures with current therapies remains limited. Medications are
the mainstay of treatment, but approximately 30% of patients
continue to have seizures despite maximal medical management
[1,2,3,4,5,6]. Furthermore, current therapies act on multiple
targets, affecting normal brain function, and often causing adverse
effects. Surgical approaches and electrical stimulation are also not
completely effective and carry significant risks.
New therapies that precisely act on specific circuit elements
during seizures may be more effective than current options, and
would minimize adverse side effects. Dramatic developments in
using genetics for optical control of neuronal activity have raised
the possibility of an entirely new method for studying and
controlling seizures [7,8]. Placing microbial opsins responsive to
light of certain wavelengths under control of specific promoters
enables targeting of expression to specific neuronal populations,
thus allowing control of selected neural circuits.
In this exploratory study we tested the feasibility of the
optogenetic approach in an in vivo animal model of epilepsy. We
used the lithium-pilocarpine rat model as it has been extensively
studied and produces very robust seizures reliably with little
variability [9,10,11,12]. We hypothesized that light-activated
inhibition can impede development of status epilepticus in
awake-behaving rodents and decrease the electrographic or
behavioral extent of the seizure. To test this, we transduced
glutamatergic hippocampal neurons in adult rats using viral
vectors carrying a potent optogenetic inhibitor, enhanced
halorhodopsin (eNpHR3.0), and fluorescent marker yellow fluo-
rescent protein (YFP) under control of the excitatory neuron-
specific calcium/calmodulin-dependent protein kinase II alpha
promoter (CaMKIIa) [13,14,15,16]. We examined whether
inhibition of eNpHR-expressing excitatory neurons by illumina-
tion during seizure onset can modulate the spatial and/or
temporal extent of seizure activity and its dynamics. Our results
demonstrate the potential for optogenetic approaches for seizure
control and the dissection of their complex neural mechanisms.
These proof-of-principle experiments are a first step towards
developing future optogenetic treatments whereby precise spatio-
temporal control over specific circuit elements will target
treatment to only those neuronal elements responsible for seizure
activity and thereby sparing normal brain function, thus over-
coming one of the major disadvantages of current pharmacological
treatments.
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e62013
Methods
All procedures were performed in accordance with institutional
and national guidelines for animal care and use for research
purposes and the study protocol was approved by the Massachu-
setts General Hospital institutional review board (IACUC, pro-
tocol # 2009N000051).
Virus
Recombinant adeno-associated virus (AAV) vector carrying
Halorhodopsin (eNpHR) gene tagged with a fluorescent marker
protein (yellow fluorescent protein, YFP) under the control of the
CaMKIIa promotor was prepared at the University of North
Carolina Vector Core Facility (rAAV5/CaMKIIa-eNpHR3.0-
eYFP). The titer of the concentrated virus for in vivo injection was
361012 virus molecules/ml.
Injection/light Delivery System Design
In order to deliver the virus and to manipulate transduced
neurons by light while recording neuronal activity we developed
a custom designed injection-recording system. It consisted of
a pedestal, electrodes and optical fiber guide, through which the
viral vector and optical fiber were introduced during the
experiment. A custom made plastic pedestal with 6 openings
(Plastics One) was secured to the skull using dental acrylic cement
(GlassLute, Pulpdent). Five openings were used to connect the
reference, two cortical and two hippocampal electrodes. A 20 ga
guide cannula was molded into the sixth opening to act as an
optical fiber guide. The tip of the twisted electrode used to record
from the hippocampus was aimed at the location of the injection.
To inject the virus, a 26 ga injection cannula was lowered through
the guide cannula into the hippocampus and the virus was
deposited. During the experiment, an optical fiber (crossection
200 mm, BFL37–200, ThorLabs) was lowered through this same
guide cannula to the stereotaxic position of the virus injection to
allow illumination of transduced neurons.
Recording System
Electrodes were connected to a multi-channel USB Biosignal
amplifier (Guger Technologies) via the pedestal using a five
channel custom cable (Plastics One) secured to the optical fiber.
The optical fiber was coupled to a 561 nm laser (CrystaLaser)
through an FC/PC connector. The laser was gated by a digital
computer pulse (TTL) delivered via the parallel port of a laptop
computer. EEG was recorded at a sampling rate of 256 or 512 Hz
with bandpass filtering from 0.1 to 100 Hz. Video recordings were
also taken of each experiment for behavioral analysis.
Surgery: Injection System/electrode Implantation
Adult male Sprague-Dawley rats were used in this study. Rats
were anaesthetized with pentobarbital (50 mg/kg). The top of the
head was shaved, and the animal was immobilized in a stereotaxic
frame. The skin was opened to expose the skull. Three small burr
holes were drilled in the skull: two 1 mm anterior to bregma,
1.5 mm lateral to the midline over each hemisphere, and one
4 mm posterior to bregma, 2.5 mm lateral to the midline on the
right side. Surface recording electrodes (two stainless steel jeweler’s
screws, shaft diameter 1.2 mm, length 1.6 mm, Plastics One) were
inserted in the right and left frontal locations. A twisted–wire
electrode coupled to the guide cannula was lowered into the
hippocampus to a depth of 3 mm according to the atlas of Paxinos
and Watson via the third hole [17]. The electrodes were
externalized through the pedestal and the installation was
mounted to the skull using acrylic cement. For pyramidal neurons
transduction, 4–6 ml of viral construct were slowly pressure
injected into hippocampus at a rate of 0.5–1 ml/min using
a 26 ga injection needle lowered through the guide cannula.
The injection needle was left in place for 5 min and then gradually
withdrawn. The pedestal was covered with a cap to prevent the
clogging of connections. Postoperatively, animals were monitored
until awaking and then returned to the animal facility.
Seizure Induction and Monitoring
Following the recovery period, seizures were induced using the
lithium-pilocarpine model. Animals received 127 mg/kg lithium
hydrochloride i.p. 18–24 hours prior to injection of pilocarpine for
seizure induction. On the experimental day scopolamine methyl
bromide 1 mg/kg was injected i.p. 30 min before injection of
pilocarpine to prevent peripheral cholinergic-agonist induced side
effects. Electrodes were connected through the head pedestal to an
EEG amplifier system, and the recording was started. To initiate
seizures pilocarpine, a muscarinic cholinergic agonist, (30 mg/kg)
was injected i.p. and the recording continued. After seizures
developed the recording continued for another 20–30 min and
then pentobarbital (100 mg/kg i.p.) was used to stop the seizure.
Animals were then perfused transcardially with phosphate
buffered saline (PBS) followed by 10% formalin, and the brains
were dissected and processed for histology.
Data Analysis
EEG recordings were downsampled, when necessary, to
a common sampling rate of 512 Hz to allow for standardized
analyses to be performed across recordings. To obtain time-
frequency representations of the seizures, a short-time fast Fourier
transform was performed using a sliding Hamming window
1000 ms long, overlapped by 500 ms. Line-length [18] was also
computed in sliding 3 second windows (overlapped by 1.5 s) for
the entire recording in each animal. The line-length feature
reflects the changes in the waveform and is a measure of the
amplitude and frequency dynamics of the seizure. To quantify the
relationship between the activity in hippocampal and cortical
electrodes, phase synchrony and cross-correlation were computed
between pairs of electrodes in 1 second windows (overlapped by
500 ms). The frequencies used were 2–50 Hz. All data are
presented as mean6SEM. Comparisons between the experimental
groups were made using one-way ANOVA, and corrected for
multiple comparisons using the Holm-Sidak method.
To characterize the dynamics and evolution of the seizures,
cumulative line-length was computed for 25 minutes from the start
of each seizure. The cumulative line length, LLcum, is the running
sum of distances between successive points within an expanding
window of size n, always starting at point 1, and was defined as
LLcum(n)~
Pn
k~1 Dx(k{1){x(k)DPN
k~1 Dx(k{1){x(k)D
where x[k] is the signal at the kth sample, and N is the total
number of points in the signal. This makes the cumulative line
length monotonically increasing from 0 to 1 over the length of the
signal. A seizure with constant power throughout the 25 minutes
would yield a straight line from 0 to 1, a seizure which slowly
increased in amplitude would be concave-up and lie below this
line, while a seizure which started strong and leveled off would be
concave-down and lie above this line. To test for differences
between the cumulative line-lengths of the experimental groups,
a non-parametric, cluster-based statistical test was utilized [19].
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Behavioral seizure manifestations were rated on the Racine
scale in 30 second epochs based on review of videorecordings of
the experiments [20]. Differences between the group scores were
tested using the same non-parametric, cluster-based statistical test
as above [19].
High-gamma Power Analysis
Spectral analysis of the hippocampal LFP was performed using
the Chronux toolbox for Matlab [21]. The high-gamma band was
defined as 70–110 Hz. Power in the high-gamma power band was
calculated over 5 second intervals using a time-bandwidth product
of 1 and 1 taper. The high-gamma power in the 5 second period
immediately preceding the onset of the light was defined as the
baseline power. Power in all subsequent 5 second periods was
normalized by dividing by the baseline power. This made it easier
to make comparisons across different animals and conditions.
Normalized power in subsequent bins was compared to baseline
using the Mann-Whitney U test.
Experimental Design
Sham control group. Animals in this group were implanted
with electrodes and guide cannula (for optical fiber introduction),
but no virus was injected. Animals were allowed to recover for 9–
14, 16–21, or 31–35 days after electrode implantation (n = 4,
n = 5, n = 4 respectively). Following the recovery period, seizures
were induced using the lithium-pilocarpine model.
NpHR control group. This group is designed to control for
the possible effect of the viral construct per se. Seven animals were
implanted with electrodes and guide cannula (for optical fiber
introduction), and viral construct was injected. Following the
recovery period (13–27 days), seizures were induced using the
lithium-pilocarpine model, but no light was delivered via the
introduced optical fiber.
Light control group. This group is designed to control for
the possible effect of light. Eight animals were implanted with
electrodes and guide cannula (for optical fiber introduction), but
no virus was injected. Following the recovery period (10–29 days),
seizures were induced using the lithium-pilocarpine model, and
light delivered via the optical fiber similar to the experimental
group.
Experimental groups. Experimental attempts to control
seizures by light were conducted 13–23 days following electrode
implantation and virus injection. Electrodes and the optical fiber
were connected to the recording system/laser as discussed above.
The laser output power was set to 35 mW (fiber output power
18 mW as measured using a power meter (PM100D, ThorLabs)),
corresponding approximately to light intensity of 570 mW/mm2.
We based light manipulation parameters on those found in
literature in other in vivo systems [14,15]. After 10 minutes of
baseline recording, 30 mg/kg pilocarpine was injected i.p. to
initiate the seizure. Experiments were conducted using one of the
following two protocols.
Continuous illumination protocol. Five to ten minutes
after injecting pilocarpine (860.9 min), irrespective of visualized
electrographic activity but designed to be 1–2 min before earliest
anticipated seizure start according to our control group data, the
laser was continuously activated until the seizure was terminated
with pentobarbital overdose.
Intermittent/triggered illumination protocol. In a differ-
ent set of experiments illumination was initiated when a change in
the EEG suggestive of early evolving seizure activity or a change in
the behavior of the animal was observed. In this circumstance the
laser was turned on for periods of 1 to 2 min, with at least 1
minute between light pulses, until the seizure was stopped with
pentobarbital overdose. This non-continuous triggered illumina-
tion began approximately 7–8 min after injecting pilocarpine
(7.460.2 min).
Animals from experimental and control groups were alternated.
Final histological confirmation of injection and eNpHR expression
success was done post-experimentally, therefore investigator was
blinded to the experimental outcome.
Estimation of Tissue Affected by Light
According to Gradinaru et al. (2009), light power sufficient to
activate eNpHR (1 mW/mm2) is present at least within 1.5 mm
distance of the fiber tip using 30 mW light source. We used a laser
output power of 35 mW, with measured fiber power output of
18 mW with a 200 mm diameter fiber, corresponding approxi-
mately to a light intensity of 570 mW/mm2. Based on the light
penetration curve for 561 nm light [15], light intensity sufficient to
activate eNpHR was present at a distance of at least 2 mm from
the light source.
Results
We attempted to control acute seizures in awake-behaving rats
in the lithium-pilocarpine model of elicited seizures using an
optogenetic approach. Hippocampal pyramidal neurons were
transduced with a virus carrying eNpHR in vivo and seizure
manipulation attempts were made using light delivered to
hippocampus via an optical fiber. Yellow light illumination of
transduced neurons prior to seizure onset significantly delayed
electrographic and behavioral initiation of status epilepticus, and
altered the dynamics of ictal activity development.
Implant Tolerability and Injection Assessment
The tolerability of the implant used for recordings, virus
injection and light delivery to the hippocampus was assessed in
a control group of animals. Following the implantation, tissue
damage was limited to the immediate proximity of the electrodes
(200–400 mm) with no regions devoid of neurons present
elsewhere in the hippocampus and cortex at any of the survival
time points (12–35 days; n = 12), showing that the implant was
well tolerated. In addition, in virally-transduced animals, pyrami-
dal neurons located in the area surrounding the implant expressed
eNpHR, suggesting that these neurons were healthy as evidenced
by intact cellular machinery.
In animals transduced with AAV, the transduction extent was
verified in histological sections of the brain following the
experiment. Hippocampal neurons were transduced successfully
and virus was expressed predominantly in pyramidal cells and
granule cells in dentate gyrus, as demonstrated by fluorescent
signal from YFP. The full medio-lateral extent of hippocampal
pyramidal layer neurons was labeled (CA1, CA2), with labeling
extending to CA3 in the dorso-ventral dimension. Transduced
neurons extended over 3.5 mm antero-posteriorly, with minimal
spread of at least 2 mm (Fig. 1). Some cortical neuron labeling
occurred as well.
Controls
We first characterized the course of seizure development in
a sub-group of sham control animals which were not transduced
with eNpHR. After gathering this initial information we con-
ducted experiments with experimental and the different control
groups interleaved. Pilocarpine injection reliably induced seizures
in all of the control rats. Seizure onsets occurred 15.261.1 min
following pilocarpine injection (n = 13, Fig. 2, 3). The seizure start
was characterized by an almost simultaneous appearance of low
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frequency, low amplitude epileptiform spike activity on cortical
electrodes in both hemispheres and hippocampal electrodes. In
most cases this activity was intermittent initially and involved
lower frequencies (20 Hz and below) and amplitudes (,500 mV).
Over 0.5–3 minutes the activity evolved into continuous spike and
spike-wave activity, and subsequently became a fully developed
seizure characterized by the presence of higher frequencies (up to
50 Hz) and amplitudes (up to or greater than 500 mV) as has been
detailed previously [11]. Immunohistochemical staining demon-
strated significant upregulation of activity-regulated immediate
early gene Arc expression in hippocampus and especially in
dentate gyrus bilaterally following seizure as compared to naı¨ve
controls (not shown), as indicative of neuronal activity induced by
seizures [22,23]. Behaviorally, the animals followed a pattern well
described for this model, characterized by facial movements (e.g.
chewing, jaw-opening), head nodding, automatisms of the
extremities, followed by myoclonic jerks and clonic seizures with
rearing, falling and loss of postural control [11,12,24]. Mild
behavioral manifestations (i.e. mouth movements, chewing) pre-
ceded the appearance of spike activity on the EEG by 1–3 min
(Fig. 4). The evolution of behavioral seizure manifestations
accompanied their electrophysiological development.
Two additional control groups were designed to assess for
possible effects of the NpHR transgene and the light. In the first,
hippocampal neurons were transduced with the virus, the optical
fiber was introduced, but no light manipulation was applied during
the course of the experiment (NpHR control). The delay before
seizure start in this group was similar to that of the original control
Figure 1. Hippocampal pyramidal neurons expressing eNpHR-EYFP, as visualized by marker protein YFP fluorescence. A.
Photomicrograph showing bilateral extent of the labeling in hippocampus. B. Higher magnification of the boxed region in A demonstrating the
morphology of transduced neurons in more detail. Arrowhead and arrow designate the tracks left by the guide cannula and recording electrode,
respectively. Notice the high density of transduced cells in the hippocampal pyramidal cell layer. Scale bars: 500 mm (A); 50 mm (B).
doi:10.1371/journal.pone.0062013.g001
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group with no virus injected (17.361.3 min, n = 7, p = 0.4, one
way ANOVA followed by Holm-Sidak method for multiple
comparisons versus the control group). In the additional control
group (light control) no virus was injected and light was delivered
via the optical fiber similar to the experimental group. Seizure
onset delay in this group was 16.361.7 (n = 8) similar to the sham
control group (p = 0.66, one way ANOVA followed by Holm-
Sidak method for multiple comparisons versus the control group).
To confirm inhibition of transduced hippocampal neurons by
light and to control for the effect of prolonged inhibition of
pyramidal hippocampal neurons and possible rebound activity
after light discontinuation, illumination was tested in animals
expressing eNpHR in the absence of seizures. Our experimental
design did not allow recording from single units to confirm
inhibition directly, therefore we used high frequency oscillations as
a surrogate for spiking activity. In particular, high-gamma
oscillations in the 70–110 Hz range are strongly correlated to
spiking activity [25]. In an animal expressing eNpHR in the
absence of seizures, we delivered 5 second pulses of light,
separated by intervals of 30 seconds (N = 35 pulses) and analyzed
the spectral content of the LFP recorded from the hippocampus
(Figure S1A). We found that the averaged high-gamma power was
visibly reduced when the light was switched on, in keeping with
a reduction of hippocampal activity. In 8 animals expressing
eNpHR, light was turned on for one to three minutes and then
switched off. In 7 out of 8 animals high-gamma power was
significantly reduced during the first 5 seconds of illumination,
when compared to baseline levels (Figure S1B, D, p,0.006,
Mann-Whitney U test). In subsequent 5 second illumination
window high-gamma power was reduced, though not significantly
(Figure S1B), and there was no significant reduction in following 5
second windows (data not shown). No rebound electrophysiolog-
ical activity was observed after illumination.
Optogenetic Seizure Control in vivo
We used two protocols for light-mediated inhibition of seizures:
a continuous illumination and an intermittent illumination in
which light was turned on for 1–2 minutes at 1 to 3 min intervals.
In both protocols the illumination was started 5–10 minutes
following pilocarpine injection, a few minutes before the earliest
time of the anticipated seizure start according to our control group
data. Both modes of illumination delayed the electrographic and
behavioral onset of the seizure and changed the dynamic of seizure
evolution in the same way. In these light illumination experiments,
electrographic seizures started 2161.8 min following administra-
tion of pilocarpine (n = 16, Fig. 2, 3), resulting in an average delay
of 6 minutes relative to the sham control group (p = 0.007).
In addition to affecting the time to onset of electrographic and
behavioral (Fig. 4) seizure activity, optogentic manipulation also
resulted in changes in early seizure dynamics. After the initiation
of seizure activity, optogenetic inhibition generally delayed the
development of high amplitude continuous oscillations (fully
developed seizure) involving 20–50 Hz activity. The seizures of
the experimental animals were characterized by an initial period
of low-amplitude, low-frequency oscillations with episodes of
remission exhibiting almost normal EEG activity. This is in
contrast to the sustained and early transition to high frequency,
high amplitude activity seen in control animals. In three animals
only short bursts of activity occurred around average seizure onset
time, followed by normal EEG activity, with clear seizure activity
not beginning for another 7–10 min in two animals, and not
occurring at all in the third. In this animal light was turned off
after 35 min, and seizure activity occurred 15 min later.
To quantify the dynamics of seizure development we calculated
the cumulative line-length for cortical and hippocampal channels
as a measure of the amplitude and frequency dynamics of each
seizure [26]. Experimental animals, compared to controls, showed
shallower slopes of cumulative line-length reflecting a slower
evolution of seizure activity from initiation to peak seizure activity
(Fig. 5; p,0.05). Phase synchrony and cross-correlation between
pairs of electrodes (cortical left vs right, cortical vs hippocampal,
hippocampal vs hippocampal) decreased following onset of the
seizure, especially between cortical and hippocampal electrodes
(not shown). There were no consistent changes associated with
illumination alone in phase-synchrony or cross-correlation be-
tween pairs of the electrodes.
Interestingly, analysis of the spectral content of the LFP
recorded from the hippocampus in experimental animals (expres-
sing eNpHR, when light was turned on following seizure induction
by pilocarpine) revealed that even in the presence of pilocarpine
exerting its proconvulsive effects, 10 out of 12 animals showed
significantly reduced high-gamma power during the first 5 seconds
of illumination (p,0.004, Mann-Whitney U test; Figure S1C, D),
while control animals (not expressing eNpHR) injected with
pilocarpine showed no change (n = 7, Figure S1D), further
supporting the suggestion that the delay in seizure onset is
specifically related to light-mediated inhibition of hippocampal
pyramidal cells.
Discussion
We successfully introduced optogenetic probes into pyramidal
neurons of the hippocampus and subsequently recorded from and
directed light into those structures in a freely behaving animal.
Inhibiting activity in primary excitatory hippocampal neurons
with light delayed status epilepticus onset in the lithium-
pilocarpine epilepsy model. This result suggests that seizure
activity originating in the hippocampus may be crucial for seizure
Figure 2. Bar graph showing time to seizure onset following
pilocarpine injection in control animals, animals expressing
eNpHR with no light manipulation (control eNpHR), light
control animals and experimental eNpHR-transfected animals.
Experimental group is significantly different from the control group,
(p = 0.007, one way ANOVA followed by Holm-Sidak method for
multiple comparisons versus the control group). Error bars represent
SEMs.
doi:10.1371/journal.pone.0062013.g002
Optogenetic Seizure Onset Delay In Vivo
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e62013
Figure 3. Plot showing EEG recordings in representative examples of sham, transduced non-illuminated and light control animals
(A, B and C respectively), and transduced illuminated (D) rats. The seizure was terminated by pentobarbital administration in each case
(arrowhead). Color spectrogram represents time-frequency distribution (scale is 0 to 50 Hz) and blue line represents the EEG recording (mV, scale 0 to
600 mV). Black vertical lines mark pilocarpine administration at time 0, vertical blue lines mark the beginning of the seizure. Yellow shading under the
time axis indicates illumination with yellow light. Blue traces overlaid on the spectrograms show windowed line-length over the course of the seizure.
doi:10.1371/journal.pone.0062013.g003
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development and subsequent propagation to the cerebral cortex in
this model [27,28]. Our results suggest that inhibiting specific
neuronal populations at the seizure initiation zone with light has
a potential for controlling epileptic activity.
High-gamma power reflects neuronal spiking activity and its
suppression following illumination suggests inhibition of trans-
duced hippocampal neurons by light, as has been demonstrated
directly by electrophysiological in vitro studies of NpHR-trans-
duced neurons [8,13]. These data support the hypothesis that the
delay in our in vivo epilepsy model is due to the inhibitory effect of
light on activity of transduced neurons.
The NpHR light-driven inhibition acts by shifting the mem-
brane potential and hyperpolarizing neurons; Zhang et al [13]
demonstrated that NpHR mediated inhibition remains stable over
long timescales. While intracellular accumulation of chloride in
pyramidal neurons could cause a depolarizing shift in the GABAA
receptor reversal potential [29], Kokaia’s group [8,30] showed
that activation of transgene NpHR does not alter the reversal
potential for the GABAA receptor-mediated monosynaptic in-
hibitory postsynaptic currents in principal hippocampal neurons in
an in vitro epilepsy model. Furthermore, it is unlikely that GABA
had become transiently excitatory and contributed to the
epileptiform activity in our experiment, because seizure onset
was delayed in our experimental design, and gamma power
analysis supported silencing of hippocampal pyramidal neurons by
NpHR activation.
The fact that unilateral inactivation was sufficient to produce
this result raises the possibility that each hippocampus plays a role
in the network of activated structures necessary for seizure
evolution. Removing one portion of this network alters the
ictogenic process. These results are in line with findings reported
for kainate model of epilepsy in mice [31], where spatially limited
unilateral silencing of pyramidal neurons abolished over half of the
seizures.
Two illumination protocols, tested for efficiency and safety
reasons, produced similar results, suggesting that the inhibition
produced in both modes is sufficient to delay the seizure onset,
likely by delaying development of activity to the level necessary to
evolve into seizure, while not causing obvious adverse behavioral
or electroencephalographic effects. Slower dynamics of early
seizure evolvement in experimental animals as demonstrated by
cumulative line-length also points toward suppression of neuronal
activity and delay in its development leading to interruption in
‘‘orchestration’’ of activity between neuronal populations into high
amplitude oscillations. Controls further confirm that seizure delay
is due to light-mediated inhibition of the hippocampal neurons
expressing eNpHR. First, eNpHR expression by itself does not
affect seizure development time, as animals which expressed
eNpHR, but were not exposed to light, showed no delay of seizure
onset. Second, illumination of transduced hippocampal neurons in
the absence of seizure resulted in no rebound activity after light
discontinuation. These finding are in line with Tonnesen et al [8],
who demonstrated in vitro that expression of NpHR transgene
alone has relatively limited effects on the properties of neurons.
Therefore, the inhibition and subsequent release from inhibition in
the intermittent illumination case was unlikely to be adding drive
toward ictal activity. Illumination in non-transduced animals did
not delay seizure onset and was not associated with decrease in
high gamma-power, further proving that the effect was mediated
by light manipulation of the transduced neurons.
The modest scale of seizure attenuation in this study is in
accordance with the extent of the hippocampal area affected by
light and experimental design used. This may have contributed to
the fact that illumination did not produce a visible change in cross-
correlation or phase synchrony between the electrodes. The study
was designed as an exploratory study of applying optogenetic
approach for control of seizures, therefore we applied a minimal
intervention approach and affected circuitry involved in seizures
unilaterally. Even unilateral intervention was powerful enough to
produce seizure delay. Since the epilepsy model used in our study
is not focal, many of the neurons that contribute to the seizure are
beyond the range of the unilateral optical fiber light inhibition. In
addition, in this model pilocarpine used to induce the seizure
remains present in the system and continues to exert proconvul-
sant activity long after the start of the light triggered inhibition
[32,33]. In line with our data, Bittencourt and colleagues were
able to delay, but not abolish pilocarpine-induced seizures by
muscimol microinjection prior to pilocarpine administration [34].
Figure 4. Behavioral seizure progression on the Racine scale in the control (sham, eNpHR, light controls, total of 11 control
experiment video recordings were rated) and experimental (N=17) groups. Behavioral manifestations of the seizure were delayed in
experimental animals as compared to the controls. Area shaded in gray marks the timepoints at which group scores differed significantly (non-
parametric, cluster-based statistical test, p,0.05).
doi:10.1371/journal.pone.0062013.g004
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Given this, one would not expect seizures to be completely blocked
by our current approach. Future experiments will be necessary to
test whether more extensive pyramidal neuron inhibition (e.g. by
bilateral or multiple optical fiber arrays) will be required for
seizure abrogation by light in this model and to determine its exact
extent. In line with this, recent studies have demonstrated
possibility of seizure control in focal epilepsy models, where
location of the epileptic focus is known and can be specifically
targeted [35], [36].
A number of other limitations could be addressed by future
experiments. Epilepsy is thought to result from an imbalance in
excitatory and inhibitory activity [37,38,39]. In this study we limit
our approach to inhibiting excitatory neurons. NpHR-YFP was
expressed predominantly in pyramidal cells and granule cells in
dentate gyrus, as confirmed by morphology, but this was not
assessed quantitatively. Possible effects of non-specific expression,
such as silencing of inhibitory cells, which could cause pro-
epileptogenic activity can’t be completely ruled out, though
selectivity of this construct expression under CaMKIIa promotor
to excitatory glutamatergic neurons has been demonstrated [8,15].
An alternative approach may test potentiation of hippocampal
inhibitory circuitry, by using viral constructs carrying excitatory
channels such as channelrhodopsin under inhibitory neuron
promoters. Combining expression of both types of optogenetic
Figure 5. Early seizure dynamics differ with optogenetic manipulation. Cumulative line-length, or path-length, of the cortical EEG recording
in control (red, N= 14, from sham and additional control groups) and experimental (blue, N = 16) rats from onset to 25 minutes into the seizure,
reflect changes in power and frequency on the standardized scale (Y axis). Areas with shallow slopes indicate lower seizure activity, while steep slopes
indicate increased amounts of seizure activity as measured by line-length. A and B show individual animal plots for cortex and hippocampus,
respectively. C and D show mean path-length 6 SEM (represented by line and shading) of the control and experimental animals in cortex and
hippocampus, respectively. The gray shaded box designates the time points at which cumulative line-length was statistically different between
control and experimental animals (non-parametric, cluster-based statistical test, p,0.05).
doi:10.1371/journal.pone.0062013.g005
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modulation constructs may provide the best mode of control, and
remains to be tested.
Further steps will include optimizing the timing of light
manipulation with regard to prospective seizure onset [40]. There
is a growing evidence for ictal activity present in small domains
[41,42] or at the level of individual neurons [43], before the onset
of a seizure is visible on EEG or has a behavioral manifestation.
These periods, when ictal activity is most spatially confined might
be the most susceptible to optogenetic control. An automatic light
triggering system responding to local electrographic activity will
enable more precise closed control loop.
In summary, our results demonstrate that inhibition of
excitatory drive in hippocampus can delay seizure onset. This
provides a proof-of-principle that this approach could be used in
the future for treatment of seizures and the dissection of epilepsy
mechanisms.
Supporting Information
Figure S1 High-gamma power is transiently suppressed
during illumination. A. Averaged LFP spectrogram in re-
sponse to 5 second pulses of light delivered with 30 second
intervals between each pulse (N = 35 pulses). Note the clear
decrease in high-gamma power across most frequencies during the
periods of illumination (green bar). B, C. High-gamma power is
decreased during the first 5 seconds of prolonged illumination
(lasting 1–3 minutes) in animals expressing eNpHR, but not during
any subsequent 5 second periods. This is true both in the absence
(B) and presence (C) of pilocarpine to induce seizures. D. Bar and
whisker plot of changes in high-gamma power during the first 5
seconds of illumination. Power is decreased in animals expressing
eNpHR (red and blue bars), but is non-significantly increased in
control animals that do not express eNpHR. This suggests that
light-activated hyperpolarization of eNpHR expressing pyramidal
cells is playing a role in decreasing high-gamma power. Median
(horizontal line), 25–75 percentiles (box) and 2.5–97.5 percentile of
the data (whiskers) are shown.
(TIFF)
Methods S1 Histological processing of the brain and
immunohistochemistry. The brains were dissected and
processed for histology for injection site/electrode location and
virus expression confirmation. Following postfixation in 10%
formalin for 2–4 hours at room temperature, brains were
cryoprotected in PBS containing 20% sucrose and 0.02% sodium
azide at 4uC, cut in serial coronal sections 40 mm thick on
a freezing microtome and stored in PBS-azide. Sections were
mounted on slides and evaluated for direct identification of YFP
expressing cells using fluorescent microscope. For histological
evaluation sections were stained with Cresyl Violet or Hematox-
ylin and Eosin. Fluorescence immunostaining of free-floating
sections was performed to visualize endogenous expression of
activity-regulated immediate early gene Arc and to amplify YFP
signal from the viral transgene. Briefly, sections were blocked for
1 hour at room temperature with 10% (v/v) normal goat serum
(NGS, Jackson Immunoresearch) in PBS containing 0.1% (v/v)
Triton X-100 (PBST) and then incubated overnight at 4uC with
primary antibodies diluted in PBST containing 3% NGS. A
monoclonal mouse anti-GFP antibody that recognizes YFP (clone
3E6, Invitrogen) was used at 1:1000 dilution, and a polyclonal
rabbit anti-Arc antibody (gift of Dr. P. Worley) was used at 1:4000
dilution. After four rinses with PBST, sections were incubated for
2 hours at room temperature with secondary antibodies, Alexa
488-conjugated goat anti-mouse IgG and Alexa 633-conjugated
goat anti-rabbit IgG (Invitrogen), each at 1:250 dilution. Sections
were rinsed four times with PBST and mounted on slides with
Fluoromount (Sigma-Aldrich). Sections were evaluated and images
acquired using an inverted epifluorescence microscope (Nikon)
equipped with appropriate filters to selectively visualize each
fluorophore, and montages covering the hippocampus were
assembled using Volocity software (PerkinElmer).
(DOCX)
Acknowledgments
We thank Drs. Andrew Cole, Matt Bianchi, and members of Dr. Cash’s
laboratory for their insightful comments on the manuscript, especially
Justine Cormier.
Author Contributions
Developed the model, conducted the experiments and wrote the first draft
of the paper: IS. Performed immunohistochemical staining and part of the
experiments: VRR. Designed and built the acquisition system: AMC SSC.
Developed and contributed the vector: KD CR VG. Discussed the results
and implications and reviewed and commented on the manuscript: IS
AMC OJA VRR VG CR KD AKM SSC. Conceived and designed the
experiments: SSC IS AKM. Performed the experiments: IS VRR.
Analyzed the data: IS AMC OJA SSC. Contributed reagents/materials/
analysis tools: KD CR VG. Wrote the paper: IS SSC AMC OJA.
References
1. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH (2010) Teratogenic effects of
antiepileptic drugs. Expert Rev Neurother 10: 943–959.
2. Annegers JF, Coan SP (2000) The risks of epilepsy after traumatic brain injury.
Seizure 9: 453–457.
3. Keranen T, Riekkinen PJ, Sillanpaa M (1989) Incidence and prevalence of
epilepsy in adults in eastern Finland. Epilepsia 30: 413–421.
4. Keranen T, Sillanpaa M, Riekkinen PJ (1988) Distribution of seizure types in an
epileptic population. Epilepsia 29: 1–7.
5. Zarrelli MM, Beghi E, Rocca WA, Hauser WA (1999) Incidence of epileptic
syndromes in Rochester, Minnesota: 1980–1984. Epilepsia 40: 1708–1714.
6. Cramer JA, Mintzer S, Wheless J, Mattson RH (2010) Adverse effects of
antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother
10: 885–891.
7. Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K (2005) Millisecond-
timescale, genetically targeted optical control of neural activity. Nat Neurosci 8:
1263–1268.
8. Tonnesen J, Sorensen AT, Deisseroth K, Lundberg C, Kokaia M (2009)
Optogenetic control of epileptiform activity. Proc Natl Acad Sci U S A 106:
12162–12167.
9. Turski WA, Cavalheiro EA, Schwarz M, Czuczwar SJ, Kleinrok Z, et al. (1983)
Limbic seizures produced by pilocarpine in rats: behavioural, electroencepha-
lographic and neuropathological study. Behav Brain Res 9: 315–335.
10. Honchar MP, Olney JW, Sherman WR (1983) Systemic cholinergic agents
induce seizures and brain damage in lithium-treated rats. Science 220: 323–325.
11. Jope RS, Morrisett RA, Snead OC (1986) Characterization of lithium
potentiation of pilocarpine-induced status epilepticus in rats. Exp Neurol 91:
471–480.
12. Persinger MA, Makarec K, Bradley JC (1988) Characteristics of limbic seizures
evoked by peripheral injections of lithium and pilocarpine. Physiol Behav 44:
27–37.
13. Zhang F, Wang LP, Brauner M, Liewald JF, Kay K, et al. (2007) Multimodal
fast optical interrogation of neural circuitry. Nature 446: 633–639.
14. Gradinaru V, Thompson KR, Deisseroth K (2008) eNpHR: a Natronomonas
halorhodopsin enhanced for optogenetic applications. Brain Cell Biol 36: 129–
139.
15. Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K (2009)
Optical deconstruction of parkinsonian neural circuitry. Science 324: 354–359.
16. Sohal VS, Zhang F, Yizhar O, Deisseroth K (2009) Parvalbumin neurons and
gamma rhythms enhance cortical circuit performance. Nature 459: 698–702.
17. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. San
Diego: Academic Press Inc.
18. Esteller R, Echauz J, Tcheng T, Litt B, Pless B. Line length: an efficient feature
for seizure onset detection; 2001. Engineering in Medicine and Biology Society,
2001. Proceedings of the 23rd Annual International Conference of the IEEE.
1707–1710.
Optogenetic Seizure Onset Delay In Vivo
PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e62013
19. Maris E, Oostenveld R (2007) Nonparametric statistical testing of EEG- and
MEG-data. J Neurosci Methods 164: 177–190.
20. Racine RJ (1972) Modification of seizure activity by electrical stimulation. II.
Motor seizure. Electroencephalogr Clin Neurophysiol 32: 281–294.
21. Jarvis MR, Mitra PP (2001) Sampling properties of the spectrum and coherency
of sequences of action potentials. Neural Comput 13: 717–749.
22. Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, et al. (1995)
Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-
associated protein that is enriched in neuronal dendrites. Neuron 14: 433–445.
23. Link W, Konietzko U, Kauselmann G, Krug M, Schwanke B, et al. (1995)
Somatodendritic expression of an immediate early gene is regulated by synaptic
activity. Proc Natl Acad Sci U S A 92: 5734–5738.
24. Clifford DB, Olney JW, Maniotis A, Collins RC, Zorumski CF (1987) The
functional anatomy and pathology of lithium-pilocarpine and high-dose
pilocarpine seizures. Neuroscience 23: 953–968.
25. Ray S, Maunsell JH (2011) Different origins of gamma rhythm and high-gamma
activity in macaque visual cortex. PLoS Biol 9: e1000610.
26. Guo L, Rivero D, Dorado J, Rabunal JR, Pazos A (2010) Automatic epileptic
seizure detection in EEGs based on line length feature and artificial neural
networks. J Neurosci Methods 191: 101–109.
27. Curia G, Longo D, Biagini G, Jones RS, Avoli M (2008) The pilocarpine model
of temporal lobe epilepsy. J Neurosci Methods 172: 143–157.
28. Sharma AK, Reams RY, Jordan WH, Miller MA, Thacker HL, et al. (2007)
Mesial temporal lobe epilepsy: pathogenesis, induced rodent models and lesions.
Toxicol Pathol 35: 984–999.
29. Lillis KP, Kramer MA, Mertz J, Staley KJ, White JA (2012) Pyramidal cells
accumulate chloride at seizure onset. Neurobiol Dis 47: 358–366.
30. Kokaia M (2011) Light-activated channels in acute seizures. Epilepsia 52 Suppl
8: 16–18.
31. Krook-Magnuson E, Armstrong C, Oijala M, Soltesz I (2013) On-demand
optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat
Commun 4: 1376.
32. Omori Y, Endo T, Hara Y, Nishiyama M, Midgley I, et al. (2004) Absorption,
distribution and excretion of 14C-pilocarpine following oral administration to
rats. Arzneimittelforschung 54: 171–178.
33. Tanzer JM, Kramer PA, Schulman P, Willard AK (1995) A pharmacokinetic
and pharmacodynamic study of intravenous pilocarpine in humans. J Dent Res
74: 1845–1849.
34. Bittencourt S, Dubiela FP, Queiroz C, Covolan L, Andrade D, et al. (2010)
Microinjection of GABAergic agents into the anterior nucleus of the thalamus
modulates pilocarpine-induced seizures and status epilepticus. Seizure 19: 242–
246.
35. Yang X, Rode DL, Peterka DS, Yuste R, Rothman SM (2012) Optical control of
focal epilepsy in vivo with caged gamma-aminobutyric acid. Ann Neurol 71: 68–
75.
36. Wykes RC, Heeroma JH, Mantoan L, Zheng K, MacDonald DC, et al. (2012)
Optogenetic and potassium channel gene therapy in a rodent model of focal
neocortical epilepsy. Sci Transl Med 4: 161ra152.
37. Zhan RZ, Timofeeva O, Nadler JV (2010) High ratio of synaptic excitation to
synaptic inhibition in hilar ectopic granule cells of pilocarpine-treated rats.
J Neurophysiol 104: 3293–3304.
38. Stafstrom CE (2006) Epilepsy: a review of selected clinical syndromes and
advances in basic science. J Cereb Blood Flow Metab 26: 983–1004.
39. Raol YH, Lynch DR, Brooks-Kayal AR (2001) Role of excitatory amino acids in
developmental epilepsies. Ment Retard Dev Disabil Res Rev 7: 254–260.
40. Paz JT, Davidson TJ, Frechette ES, Delord B, Parada I, et al. (2013) Closed-loop
optogenetic control of thalamus as a tool for interrupting seizures after cortical
injury. Nat Neurosci 16: 64–70.
41. Stead M, Bower M, Brinkmann BH, Lee K, Marsh WR, et al. (2010)
Microseizures and the spatiotemporal scales of human partial epilepsy. Brain
133: 2789–2797.
42. Dichter MA (2009) Emerging concepts in the pathogenesis of epilepsy and
epileptogenesis. Arch Neurol 66: 443–447.
43. Truccolo W, Donoghue JA, Hochberg LR, Eskandar EN, Madsen JR, et al.
(2011) Single-neuron dynamics in human focal epilepsy. Nat Neurosci.
Optogenetic Seizure Onset Delay In Vivo
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e62013
